Skip to main content

Table 3 Univariate and multivariate analyses of risk factors for regimen change in the CKD patients

From: Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

 

Regimen change

Univariate

Multivariate

Yes

No

Odds ratio

95% CI

P value

Odds ratio

95% CI

P value

n = 25

n = 129

 Male, n (%)

12 (48.0%)

78 (60.5%)

0.60

0.26–1.43

0.250

1.94

0.55–6.85

0.305

 BMI, kg/m2 (mean ± SD)

19.1 ± 2.60

19.0 ± 2.66

1.01

0.86–1.19

0.858

   

CKD severity

 Mild

10 (40.0%)

83 (64.3%)

Reference

–

–

Reference

–

–

 Moderate

9 (36.0%)

34 (26.4%)

2.20

0.82–5.88

0.117

2.10

0.57–7.71

0.264

 Severe

6 (24.0%)

12 (9.3%)

4.15

1.28–13.5

0.018

5.92

1.08–32.5

0.041

Underlying disease

 Liver damage

2 (8.0%)

10 (7.8%)

1.03

0.21–5.04

0.966

   

Laboratory data

 Albumin, g/dL (mean ± SD)

2.6 ± 0.8

3.2 ± 0.8

0.41

0.23–0.73

0.003

0.68

0.31–1.46

0.320

Treatment regimen, n (%)

 HREZ

13 (52.0%)

76 (58.9%)

0.755

0.32–1.78

0.523

   

Adverse events

 Drug-induced hepatitis, n (%)

14 (56.0%)

8 (6.2%)

19.3

6.63–55.9

<0.001

35.6

8.70–145

<0.001

 Cutaneous reaction, n (%)

6 (24.0%)

5 (3.9%)

7.83

2.17–28.2

0.002

17.4

3.16–95.5

0.001

  1. BMI body mass index, CI confidence interval, CKD chronic kidney disease, HREZ isoniazid, rifampicin, ethambutol and pyrazinamide, SD standard deviation